Moreover, mutations in polymerase proofreading–associated syndrome involving POLE and POLD1 constitute 0.3–0.7% of familial cancer cases when only CRC and polyposis are considered (Mur et al. 2020). This evidence concerns the gene POLD1 and polyposis.